Leiden

• PROTECx - Pembrolizumab Registry for Outcomes and Treatment Evaluation in Cervical Cancer Pending
  2025-522883-34-00 6 Metastatic cervical cancer
• A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy Pending
  2025-522949-22-00 5 Duchenne muscular dystrophy
• A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of In … Pending
  2025-523087-20-00 5 Duchenne muscular dystrophy
• PREOPANC-6 study: dendritic cell immunotherapy after FOLFIRINOX chemotherapy in patients with resectable pancreatic cancer Pending
  2025-523134-28-00 10 ABC borderline resectable pancreatic cancer
• Study on the effect of 6qc-ICG on the skin of healthy volunteers and in patients with breast cancer during surgeries. Pending
  2025-523166-24-00 7 Breast cancer
• A Phase 1 Study of AIR-001 in Adults with AATD. Pending
  2025-523558-14-00 1 Alpha-1 Antitrypsin Deficiency
• Study to assess the efficacy and safety of Rina-S in participants with non-small cell lung cancer Recruiting
  2025-522107-18-00 4 2026-05-19 Locally advanced or metastatic Non-Small Cell Lung Cancer
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)
• A Phase 2 Study of Petosemtamab in Combination with Pembrolizumab in Adults with NSCLC Recruiting
  2025-522867-13-00 4 2026-04-27 Non Small Cell Lung Cancer
• A study to investigate the efficacy and safety of frexalimab versus tacrolimus in adults undergoing kidney transplantation Recruiting
  2025-521521-33-00 10 2026-04-02 Kidney transplant rejection
• MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth … Recruiting
  2025-522492-28-00 4 2026-03-13 AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthenia Gravis,
• Late immunity following single immunization with GA2 sporozoites (GACHA) Recruiting
  2025-524045-27-00 9 2026-03-11 Falciparum malaria
• A clinical study of new treatments for non-small cell lung cancer (MK-3475-01J) Recruiting
  2025-521939-36-00 4 2026-03-03 Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
• A Study to Evaluate Atumelnant in Adults with Congenital Adrenal Hyperplasia Recruiting
  2024-519579-24-00 5 2026-02-26 Classic Congenital Adrenal Hyperplasia
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting
  2025-520979-13-00 5 2025-12-18 Patients with HR+ HER2- early breast cancer at intermediate risk of re
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting
  2024-520356-24-00 4 2025-12-01 Refractory Metastatic Colorectal Cancer with Liver Dominant Disease
• Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting
  2025-521775-31-00 5 2025-11-12 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
• The efficacy and safety of Intramuscular Methylprednisolone in patients with Hand OsteoArthritis: the IMHOA trial Recruiting
  2024-518344-20-00 5 2025-10-28 Hand osteoarthritis
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• Long-term study to assess the safety and tolerability of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD) Recruiting
  2024-519423-24-00 5 2025-10-07 Major Depressive Disorder
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P

Showing 25–48 of 450 trials